<SEC-DOCUMENT>0001493152-23-029858.txt : 20230822
<SEC-HEADER>0001493152-23-029858.hdr.sgml : 20230822
<ACCEPTANCE-DATETIME>20230822171510
ACCESSION NUMBER:		0001493152-23-029858
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20230822
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230822
DATE AS OF CHANGE:		20230822

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celcuity Inc.
		CENTRAL INDEX KEY:			0001603454
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38207
		FILM NUMBER:		231194486

	BUSINESS ADDRESS:	
		STREET 1:		16305 36TH AVENUE N
		STREET 2:		SUITE 100
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55446
		BUSINESS PHONE:		763-392-0767

	MAIL ADDRESS:	
		STREET 1:		16305 36TH AVENUE N
		STREET 2:		SUITE 100
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Celcuity LLC
		DATE OF NAME CHANGE:	20140324
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:CELC="http://celcuity.com/20230822">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_033_CELC_celcuity.com_20230822 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20230822_20230822 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DEntityCentralIndexKey_0001603454 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2023-08-22" name="dei:EntityCentralIndexKey">0001603454</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-08-22" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="celc-20230822.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2023-08-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-22</xbrli:startDate>
        <xbrli:endDate>2023-08-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_901_edei--DocumentType_c20230822__20230822_z6d7BLnlUaml"><ix:nonNumeric contextRef="AsOf2023-08-22" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of the</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported): <span id="xdx_907_edei--DocumentPeriodEndDate_c20230822__20230822_zSpisY7Thbxg"><ix:nonNumeric contextRef="AsOf2023-08-22" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">August 22, 2023</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90A_edei--EntityRegistrantName_c20230822__20230822_z92c5OerZpHj"><ix:nonNumeric contextRef="AsOf2023-08-22" name="dei:EntityRegistrantName">Celcuity
Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of Registrant as Specified in its Charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20230822__20230822_zHP3z96XJFWh"><ix:nonNumeric contextRef="AsOf2023-08-22" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityFileNumber_c20230822__20230822_zenzjTeCjUgi"><ix:nonNumeric contextRef="AsOf2023-08-22" name="dei:EntityFileNumber">001-38207</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityTaxIdentificationNumber_c20230822__20230822_zcWtoOTWxXuk"><ix:nonNumeric contextRef="AsOf2023-08-22" name="dei:EntityTaxIdentificationNumber">82-2863566</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
    or Other Jurisdiction</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
    Incorporation)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File
    Number)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(IRS
    Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    No.)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityAddressAddressLine1_c20230822__20230822_zkmZdT1VF0J2"><ix:nonNumeric contextRef="AsOf2023-08-22" name="dei:EntityAddressAddressLine1">16305
36th Avenue North; Suite 100</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityAddressCityOrTown_c20230822__20230822_zlGLhNX23UUc"><ix:nonNumeric contextRef="AsOf2023-08-22" name="dei:EntityAddressCityOrTown">Minneapolis</ix:nonNumeric></span>,
<span id="xdx_90D_edei--EntityAddressStateOrProvince_c20230822__20230822_zkMpdHgYZmo1"><ix:nonNumeric contextRef="AsOf2023-08-22" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Minnesota</ix:nonNumeric></span> <span id="xdx_90C_edei--EntityAddressPostalZipCode_c20230822__20230822_zbe2S06oMii4"><ix:nonNumeric contextRef="AsOf2023-08-22" name="dei:EntityAddressPostalZipCode">55446</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
of Principal Executive Offices and Zip Code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--CityAreaCode_c20230822__20230822_z0wnwVk9lt75"><ix:nonNumeric contextRef="AsOf2023-08-22" name="dei:CityAreaCode">(763)</ix:nonNumeric></span>
<span id="xdx_908_edei--LocalPhoneNumber_c20230822__20230822_zp3OW0IkPPX1"><ix:nonNumeric contextRef="AsOf2023-08-22" name="dei:LocalPhoneNumber">392-0767</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Registrant&#8217;s
telephone number, including area code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>Not
Applicable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Former
Name or Former Address, if Changed Since Last Report)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--WrittenCommunications_c20230822__20230822_zKLtVN7cf8xh"><ix:nonNumeric contextRef="AsOf2023-08-22" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--SolicitingMaterial_c20230822__20230822_zUvJbj9sM4Rj"><ix:nonNumeric contextRef="AsOf2023-08-22" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--PreCommencementTenderOffer_c20230822__20230822_zu5iEPcdJma2"><ix:nonNumeric contextRef="AsOf2023-08-22" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--PreCommencementIssuerTenderOffer_c20230822__20230822_zRla2ZmpDfne"><ix:nonNumeric contextRef="AsOf2023-08-22" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--Security12bTitle_c20230822__20230822_zKyXt4oKW1ld"><ix:nonNumeric contextRef="AsOf2023-08-22" name="dei:Security12bTitle">Common
    Stock, $0.001 par value per share</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--TradingSymbol_c20230822__20230822_zUxpr1Xx3qh1"><ix:nonNumeric contextRef="AsOf2023-08-22" name="dei:TradingSymbol">CELC</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>The
    <span id="xdx_90B_edei--SecurityExchangeName_c20230822__20230822_zBmNsS5EJc92"><ix:nonNumeric contextRef="AsOf2023-08-22" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20230822__20230822_zZSZPwYb4Jac"><ix:nonNumeric contextRef="AsOf2023-08-22" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 8.01</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other Events.</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 22, 2023, the Company issued a press release to announce that it expects to initiate a Phase 1b/2 clinical trial, in the first
quarter of 2024, to evaluate patients with metastatic castration resistant prostate cancer (mCRPC). The trial is expected to evaluate
gedatolisib, the company&#8217;s pan-PI3K/mTOR inhibitor, in combination with darolutamide, an androgen receptor inhibitor, in patients
with mCRPC whose disease progressed on their first line of androgen receptor treatment for mCRPC. A copy of the press release is attached
as Exhibit 99.1 to this report and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 22, 2023, the Company issued a press release to announce entry into a clinical trial collaboration and supply agreement. A copy
of the Company&#8217;s press release is attached as Exhibit 99.2 to this report and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Form 8-K, and the press releases incorporated herein by reference, contain statements that constitute &#8220;forward-looking statements&#8221;
including, but not limited to, the timing of initiating and enrolling patients in, and receiving results from, clinical trials, such
as Celcuity&#8217;s Phase 3 VIKTORIA-1 and Phase 1b/2 CELC-G-201 clinical trial, the scope, protocol, costs and expected results from
ongoing and planned clinical trials, the skills and experience of investigators involved with Celcuity&#8217;s Phase 1b/2 CELC-G-201
clinical trial, the impact on gedatolisib and Celcuity of preliminary clinical trial results, the market opportunity for gedatolisib
in the prostate cancer market, and other expectations with respect to Celcuity&#8217;s lead product candidate, gedatolisib, and Celcuity&#8217;s
CELsignia platform. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221;
&#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221;
&#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;intends,&#8221; &#8220;goal,&#8221; or &#8220;continue,&#8221; and other similar
expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.
Forward-looking statements are subject to numerous risks, uncertainties, and conditions, many of which are beyond the control of Celcuity.
These include, but are not limited to, delays, disruptions or adverse results in the CELC-G-201 clinical trial, Bayer&#8217;s continued
performance under the terms of our clinical trial collaboration and supply agreement, and those risks set forth in the Risk Factors section
in Celcuity&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission
on March 23, 2023, and our subsequent Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Celcuity undertakes no obligation to update these statements for revisions or changes
after the date of this press release, except as required by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Exhibits. </b></span></p>



<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibits </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release, dated August 22, 2023, regarding the Company&#8217;s Phase 1b/2 clinical trial.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ex99-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release, dated August 22, 2023, regarding Clinical Collaboration and Supply Agreement.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive
    Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
August 22, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CELCUITY
INC.</b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="width: 50%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Brian F. Sullivan</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
F. Sullivan</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Executive Officer</span></p>

</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3.5in; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LXOrDHR3OlTEKTJEvK0uk+LWjLT+PZJvad0QQyAJ53w5QgzEkha6RobjrMhhj01bK4dQYIWM5ozeka3WKfhZ4EVbx8q47vyBGXkGPZOE8eTkhc561xbLFKLxUMqhHPkllQlMNyL46hmZSpdonFY1KFPCjqlljU7xq/+wV08y1Ly6qAOy1WRSiMOol98go1jClu7qQXy1kOeZCAZdBWLJdGu/MTfrqIF5jY3Psj367+ADGEpJSA== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex99-1_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Celcuity
Announces Plan to Conduct Phase 1b/2 Clinical Trial in </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Metastatic
Castration Resistant Prostate Cancer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.2in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Received
                                            FDA clearance of IND for gedatolisib in combination with darolutamide</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.2in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Virtual
                                            Science Day to be held on September 21, 2023 from 10:00 a.m. &ndash; 12:00 p.m. ET</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MINNEAPOLIS,
August 22, 2023</B> - Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies
for oncology, has been notified by the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) submission has
been reviewed, and Celcuity can proceed with the clinical development of gedatolisib in combination with Nubeqa<SUP>&reg;</SUP> (darolutamide),
an approved androgen receptor inhibitor, for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC).
Celcuity&rsquo;s Phase 1b/2 study (CELC-G-201) will enroll up to 54 participants with mCRPC who progressed after treatment with an androgen
receptor inhibitor as first-line treatment for mCRPC. The Company anticipates initiating this Phase 1b/2 clinical trial in the first
quarter of 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;We
are excited to initiate the clinical development of gedatolisib in prostate cancer,&rdquo; said Brian Sullivan, Chief Executive Officer
and co-founder of Celcuity. &ldquo;Gedatolisib&rsquo;s highly differentiated mechanism of action makes it uniquely suited to address
the complex PI3K/mTOR activity involved in this disease.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the Phase 1b portion of the study, Celcuity expects that 36 participants will be randomly assigned to receive 600 mg darolutamide combined
with either 120 mg gedatolisib in Arm 1 or 180 mg gedatolisib in Arm 2. An additional 12 participants will then be enrolled in the Phase
2 portion of the study at the RP2D level to enable evaluation of 30 participants treated with the RP2D of gedatolisib.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary objectives of the Phase 1b portion of the trial include assessment of the safety and tolerability of gedatolisib in combination
with darolutamide and determination of the recommended Phase 2 dose of gedatolisib. The primary objective of the Phase 2 portion of the
trial is to assess the radiographic progression-free survival (rPFS) at six months of patients who received the RP2D.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Treatment
options for patients with mCRPC whose disease progressed on or after treatment with an androgen receptor inhibitor are limited, and there
is an urgent need for new drugs to treat this patient population,&rdquo; said Karim Fizazi, MD, PhD, Professor of Medicine at Institute Gustave Roussy and GETUG President. Professor K. Fizazi,
who is one of the primary principal investigators for this study, further stated:
&ldquo;Since PI3K/mTOR and androgen receptor signaling are commonly aberrantly activated in mCRPC, combining gedatolisib with the approved
androgen receptor inhibitor darolutamide represents a potentially promising treatment option for these patients.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
Information for the Virtual Science Day</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity
will host a Virtual Science Day for analysts and investors on Thursday, September 21, 2023, from 10:00 a.m. &ndash; 12:00 p.m. ET, featuring
presentations by key opinion leaders and Celcuity&rsquo;s leadership. During this meeting, Celcuity will provide an in-depth scientific
overview of gedatolisib, the importance of comprehensive, rather than selective, inhibition of the PI3K/mTOR pathway, and review its
clinical development strategy, including a discussion about its Phase 1b/2 study in mCRPC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
live chat-based Q&amp;A session will follow the formal presentations. To register for the event, please click <U>here</U>. A replay of
the webcast will be available on the &ldquo;Events &amp; Presentations&rdquo; section of Celcuity&rsquo;s website for a limited time
following the event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Gedatolisib</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gedatolisib
is a potent inhibitor that selectively targets all Class I isoforms of PI3K and mTOR. Its mechanism of action and pharmacokinetic properties
are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. Inhibiting
all four PI3K isoforms, as gedatolisib does, limits the potential confounding effect of isoform interaction that may occur with isoform-specific
PI3K inhibitors. Inhibiting mTOR also addresses potential resistance mechanisms that can result when PI3K isoforms are targeted in the
absence of mTOR inhibition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Celcuity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity
is a clinical-stage biotechnology company pursuing development of targeted therapies for oncology. The company&rsquo;s lead therapeutic
candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated
from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1,
evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer
is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at <U>ClinicalTrials.gov</U>. A Phase
1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant
prostate cancer, is planned to begin enrolling patients in the first quarter of 2024. The company&rsquo;s CELsignia companion diagnostic
platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already
approved targeted therapies. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at <U>Celcuity.com</U>.
Follow us on <U>LinkedIn</U> and <U>Twitter</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains statements that constitute &ldquo;forward-looking statements&rdquo; including, but not limited to, the timing
of initiating and enrolling patients in, and receiving results from, clinical trials, such as Celcuity&rsquo;s Phase 3 VIKTORIA-1 and
Phase 1b/2 CELC-G-201 clinical trial, the scope, protocol, costs and expected results from ongoing and planned clinical trials, the skills
and experience of investigators involved with Celcuity&rsquo;s Phase 1b/2 CELC-G-201 clinical trial, the impact on gedatolisib and Celcuity
of preliminary clinical trial results, the market opportunity for gedatolisib in the prostate cancer market, and other expectations with
respect to Celcuity&rsquo;s lead product candidate, gedatolisib, and Celcuity&rsquo;s CELsignia platform. In some cases, you can identify
forward-looking statements by terminology such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expects,&rdquo;
&ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo;
&ldquo;intends,&rdquo; &ldquo;goal,&rdquo; or &ldquo;continue,&rdquo; and other similar expressions that are predictions of or indicate
future events and future trends, or the negative of these terms or other comparable terminology. Forward-looking statements are subject
to numerous risks, uncertainties, and conditions, many of which are beyond the control of Celcuity. These include, but are not limited
to, delays, disruptions or adverse results in the CELC-G-201 clinical trial and those risks set forth in the Risk Factors section in
Celcuity&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on
March 23, 2023, and our subsequent Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Celcuity undertakes no obligation to update these statements for revisions or changes
after the date of this press release, except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contacts:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity Inc.</FONT></P>
                                                                     <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Sullivan, <U>bsullivan@celcuity.com</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vicky
    Hahne, <U>vhahne@celcuity.com</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">763-392-0123</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ICR
    Westwicke</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Uhl, <U>robert.uhl@westwicke.com</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(619)
    228-5886</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex99-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><IMG SRC="ex99-2_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Celcuity
Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>to
Provide Nubeqa<SUP>&reg;</SUP> (darolutamide) for Planned Phase 1b/2 Clinical Trial</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MINNEAPOLIS,
August 22, 2023</B> - Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies
for oncology, today announced that it has entered into a clinical trial collaboration and supply agreement with Bayer AG for Celcuity&rsquo;s
Phase 1b/2 clinical trial of gedatolisib and Nubeqa<SUP>&reg;</SUP> (darolutamide) in patients with metastatic castration resistant prostate
cancer (mCRPC). As part of the supply agreement, Bayer will provide Nubeqa to Celcuity at no cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity
expects to initiate a Phase 1b/2 clinical trial in the first quarter of 2024 to evaluate gedatolisib, the company&rsquo;s pan-PI3K/mTOR
inhibitor, in combination with darolutamide, an androgen receptor inhibitor, in patients with mCRPC who progressed on their first line
of androgen receptor treatment for mCRPC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;We
are excited that Bayer is providing darolutamide for this important Phase 1b/2 clinical trial,&rdquo; said Brian Sullivan, Chief Executive
Officer and co-founder of Celcuity. &ldquo;Darolutamide is structurally unique to other ARI&rsquo;s, with an excellent efficacy and differentiated
tolerability profile coupled with minimal drug-drug interactions, making it an ideal combination partner for gedatolisib. Our goal is
to address the significant need for new therapeutic options for patients with metastatic castration resistant prostate cancer.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Gedatolisib</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gedatolisib
is a potent inhibitor that selectively targets all Class I isoforms of PI3K and mTOR. Its mechanism of action and pharmacokinetic properties
are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. Inhibiting
all four PI3K isoforms, as gedatolisib does, limits the potential confounding effect of isoform interaction that may occur with isoform-specific
PI3K inhibitors. Inhibiting mTOR also addresses potential resistance mechanisms that can result when PI3K isoforms are targeted in the
absence of mTOR inhibition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Celcuity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity
is a clinical-stage biotechnology company pursuing development of targeted therapies for oncology. The company&rsquo;s lead therapeutic
candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated
from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1,
evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer
is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at <U>ClinicalTrials.gov</U>. A Phase
1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant
prostate cancer, is planned to begin enrolling patients in the first quarter of 2024. The company&rsquo;s CELsignia companion diagnostic
platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already
approved targeted therapies. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at <U>Celcuity.com</U>.
Follow us on <U>LinkedIn</U> and <U>Twitter</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains statements that constitute &ldquo;forward-looking statements&rdquo; including, but not limited to, the timing
of initiating and enrolling patients in, and receiving results from, clinical trials, such as Celcuity&rsquo;s Phase 3 VIKTORIA-1 and
Phase 1b/2 CELC-G-201 clinical trial, the costs and expected results from ongoing and planned clinical trials, the impact on gedatolisib
and Celcuity of preliminary clinical trial results, the market opportunity for gedatolisib in the prostate cancer market, and other expectations
with respect to Celcuity&rsquo;s lead product candidate, gedatolisib, and Celcuity&rsquo;s CELsignia platform. In some cases, you can
identify forward-looking statements by terminology such as &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;expects,&rdquo; &ldquo;plans,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo; &ldquo;intends,&rdquo;
&ldquo;goal,&rdquo; or &ldquo;continue,&rdquo; and other similar expressions that are predictions of or indicate future events and future
trends, or the negative of these terms or other comparable terminology. Forward-looking statements are subject to numerous risks, uncertainties,
and conditions, many of which are beyond the control of Celcuity. These include, but are not limited to, Bayer&rsquo;s continued performance
under the terms of our clinical trial collaboration and supply agreement and those risks set forth in the Risk Factors section in Celcuity&rsquo;s
Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 23, 2023,
and our subsequent Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. Celcuity undertakes no obligation to update these statements for revisions or changes after the
date of this press release, except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contacts:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
Sullivan, <U>bsullivan@celcuity.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vicky
Hahne, <U>vhahne@celcuity.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">763-392-0123</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ICR
Westwicke</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
Uhl, <U>robert.uhl@westwicke.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(619)
228-5886</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !% -<# 2(  A$! Q$!_\0
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MGZCI\4TV,>9RK$>Y'6K^G:;::39):6$"P6Z9VHO09.35SE&6O4F*<=.AP7Q
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-5+>B*CNQ:***DH__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-2_001.jpg
<TEXT>
begin 644 ex99-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !0 /H# 2(  A$! Q$!_\0
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ME\85_9C]XMP0H.\,1U^4$ 9XVG<2.XY. :_C.^,/_*V3\'/^OKP:?P/[$WC
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MWI_F/BNTL-EB?V<_R27K_M::]+/J?VGI]]/\]VK^</\ X.BP#_P3C\!Y /\
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MY;PW,UAX8\?V5CI#RZG#;RS:/XE\-^%-9EAO=,T[4],OOP!_9L_X+F_MA_\
M!,W2M%_90_X*1?LL?$3Q&/AU9:;X4\)>,M2NE\$_$^+PWI:K8:583ZEK%M>^
M /C'I>GZ9:I:Z#XM\/>)[:YU'3K%1?:YXFF1M5;[.DLSXHX9R..18ZI'-N'L
M'6RS%Y3'-IX"OBL'];K8K"8W!4GB<-"O*G#$3H5J47*491IJ#]]H^8FL'DF=
MYD\SP:E@,TKQQM#,)82GBJ5&NZ,*5>C6;PU>=%5'356,HN,9:\R346OZB_\
MAUQ_P3='/_#"G[*7'/\ R0WX??\ RB-;O@S_ ()X?L%_#OQEX9\>^!/V/?V:
MO!GCCPAK%CKGA3Q1X;^#O@72?$'A_6K*=9[+5]&U&TTB*\TW4+66-9+6]M9(
MKB":..>.02P1E/PT\0_\'8/[%MCI-W<:%^SW^TIJFJHO^AV6M-\)_#NEW#9&
MY;K5K;XC>(+NT'EEG!AT2^;Y&\Q(T*2/ZI_P3S_X+!?M@?\ !1']L+P/H/AS
M]C#6OA5^QG'I/CU_&GQ5DLO$_B]K76K+PSJ&I>!(M8^)VHZ9X3\!VD&I:UIT
M>G2>'/">D>(/$4FI:II4DFH6V@Q7]S>>+B>'^.<+A<5BLR6:87!X:@ZM?Z_F
MU7#NI!R]E:C1JYG4J8J4I2Y73ITYW4G&4;-W]'#YMPS6Q.&I82.&Q%>I54:4
M<+E]-\L^DZDU@>6E&/Q>T=2%N6Z:LF?TH2D".0DX&QN3_NFOXPOC&RK_ ,'9
M/P=9FP'NO!:)TP0W[%7C#!R>H9L*"."> <D _P!GDV/*DSG&QLX!)Q@YQCG/
MH1R#R.:_BY_X+Q?!KXX_LB_\%#?@!_P5@^$?@J_\8>!- ;X77?CJ^C@U*YT/
MPW\1OA-J%[IHTCQW<:8DE]X<\&_%'X:/I7ABRU^-%L(-0T[Q!:W4\&H7VDVV
MJ5P,Z53,\SP$ZU.C5S;AO.LKPDJLH0ISQN)I49X6C*<YPA!UZF&=*,IRC%3G
M35[R2>G%?-# 8/$JG4J4\%F^6XO$JE%SG##4ZLU4JJ"3<HT[N4U%2:A&3MM?
M^TA71ONNK<D?*P/(.".#U!X(['@UX?\ M/?"]_C?^S7^T+\%XX$N9/B]\#OB
MS\+X[:2X6T2X?Q_X"U_PFD#W;$+;+,VK"-KAB!"&,AX6OQ$_8L_X.*OV<?VS
MOVEO@-^R_P"#?@?\4?!?C#XTW/BVQN=?\5^(? <OAGPMJOACX=>*/B!'9V;:
M-JEYJ?B.WUA/"LVA6-S+IOAV<7]]9R?8)E+(W]$]QN\F0)G<5PNW.[)('RD<
MAAU4\8;!) YKY['Y9FN18JC2S+!5,'BU&EBJ5*I*G/GBJO-3G%TYU(N+E1BM
M97=W=)-7]; X_!9OAIU,'7AB*,^:C.4%-*+G3DG&2G&#4N6;=FE:]G9W2_CP
M_P"#3'XJ:6?!G[8'P*U+.F^+].\6?#'XPVNG:C=>5J-]I'B#P]JG@CQ*(M,E
MCBG@;PEK/A?0[?7)Y &6[\5:;:M#$4#O_8F'0@$,I!Z$,"#WX(//'-?QA?\
M!03_ ()^_MF?\$WOVVM9_P""G/\ P3;\-ZSXT\#^,=:\4>+/B=\,O#'AR_\
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MD='^$OA-E964E60@@JRDA@<@D&O7OVS_ -G'0OVO/V6?CA^S5XBOCI-A\8/
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M;>*/BE*$C,EW\6/'MQ<>,/B'YES&2+NWTGQ'J]YX<T:60L\7A_1-(M486UO
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MUSQ!X0\11:<^D^,];TS64DTN?P;X>N;OQ:UV@V:.8I(6F_%C]LOP[XC\-_\
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MX2&.*!8 J+$D:(@7\A_^"67@'QWX.^.__!6W4_&O@CQSX/TWQK_P4<\<^+/
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MX<\4:?>:1!?>!6M;'2;C4K:Z\56VG6>H:7-I=W87-TNLV/F_DW^QWHFOS?\
M!*?]J_X/6_B;_@HCX\^+5M_P31O_  E?_ _]IO\ 9[^(/@7P3\+?&5I^SQ\0
M/"Z_#']EK^V?V?\ X:7_ (X2Y\077_",'1-.\2?%/6KG3O#_ ((\FY0WD-WK
M_P"?W[-W[)?[2GP$_:Y_X)!^'-/^!7Q<3X ?$7P]^QQ^V%XXU"+X8>.8-$^
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-S4I*1U-%%%>6>H?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>celc-20230822.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaqBSbP9z5Z8iekhvWB5bQnaTykkp4myfSjU49gGkWEM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:CELC="http://celcuity.com/20230822" elementFormDefault="qualified" targetNamespace="http://celcuity.com/20230822">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://celcuity.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="celc-20230822_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="celc-20230822_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>celc-20230822_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>celc-20230822_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://celcuity.com/role/Cover" xlink:href="celc-20230822.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140101184437504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 22, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 22,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Celcuity
Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001603454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-2863566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">16305
36th Avenue North; Suite 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Minneapolis<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">55446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(763)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">392-0767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CELC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="celc-20230822.xsd" xlink:type="simple"/>
    <context id="AsOf2023-08-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2023-08-22</startDate>
            <endDate>2023-08-22</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="AsOf2023-08-22">0001603454</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="AsOf2023-08-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="AsOf2023-08-22">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2023-08-22">2023-08-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2023-08-22">Celcuity Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2023-08-22">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2023-08-22">001-38207</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2023-08-22">82-2863566</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2023-08-22">16305 36th Avenue North; Suite 100</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2023-08-22">Minneapolis</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2023-08-22">MN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2023-08-22">55446</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2023-08-22">(763)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2023-08-22">392-0767</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2023-08-22">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2023-08-22">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2023-08-22">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2023-08-22">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2023-08-22">Common     Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2023-08-22">CELC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2023-08-22">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2023-08-22">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MY?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^
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M$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ Y(D65P=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" #DB197@[UVMNX    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " #DB197F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( .2)%E=8
M/H%;6 0  (T0   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " #DB197GZ ;\+$"  #B#   #0
M    @ &;#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( .2)%E>7BKL<P
M !,"   +              "  7</  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M .2)%E>JQ"(6,P$  "("   /              "  6 0  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " #DB197)!Z;HJT   #X 0  &@
M@ ' $0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #D
MB19799!YDAD!  #/ P  $P              @ &E$@  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     "0 ) #X"  #O$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>celc-20230822.xsd</File>
    <File>celc-20230822_lab.xml</File>
    <File>celc-20230822_pre.xml</File>
    <File>ex99-1.htm</File>
    <File>ex99-2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "celc-20230822_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "celc-20230822_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "celc-20230822.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "CELC",
   "nsuri": "http://celcuity.com/20230822",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "AsOf2023-08-22",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://celcuity.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "AsOf2023-08-22",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001493152-23-029858-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-029858-xbrl.zip
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MECJ[*=MCMKH_"^B" *7'7.NN;2%O@.)I!KID69+MU?-T-]O-B@A+X]H25VQ
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M][A5%$3O=SDS22BUJ"EVC,6"TR1*LH2M?Y$GGR+!ME;91*Z @ UJ&MJ*(%
M;9D<'(1(*QU#<">(@I#(CLA? E2)A<3MPX-UMN\2NX*BW["& U8& 4FO/1,6
M&3".:A&H"$%YC%]LYFFZ)>)-\%A"/"$$F@= :NE#Q DRV0M5$>B3K06)MG)^
MW$^/5\LDH[:3R[;$V9P$F*MF)*,\"#8 4R8+>1GB#VAZ_-?5WY".<MS]-WPI
ML$H>N]AO5IP"V:>L*E<0=%C4'%@D0:  ^S)IN.&HE*)"ZR,[5<.LI3E&N2L
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M(#Y#K+&+$H*ODF>6DLHG@BK/,>"10I$C/COTV,.9>UE,:MZ>>XK7=82(^TI
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M.SI N'%'&N-,YZE#4&$XJJ0\D9<.>!%S2HRD]1"()["6&'&E=).;X:&UZ$Z
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M)\W#8YB=$H2L9Z*\1P%W(U59>ES"<L) )L";I1(!&SZL;Z+-%M&[TC)5D0F
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M_,/M_]K_#V[3O[N&_W^E?Y/]/U!+ P04    " #EB197I&'X1V46   ,G0
M"P   &9O<FTX+6LN:'1M[3UI=]H\L]]S3OZ#+O<^[TG/$_8E:WD/(:0E*P72
MI/F2(VP!"L9V;)FEO_[.2#9@EC1)R5+29VD:6QK-KM%H).__=] U2(\Y+K?,
MSY%D+!$AS-0LG9NMSQ%/-*/;D?_FU]?VVP+:05O3_1QI"V'OQN/]?C_63\<L
MIQ5/[NSLQ ?8)J(:[0[FMDLE$LGX]=EI36NS+HURTQ74U-BHD\'-SF+X^';4
MM.$8/-04GP2#I.,SH.&M/NXPV3@75R]#3<7<IEG55 1-N6ME4LFMA_!0+48=
M!HO:)A%GH)!='U1/Q\W%_/;CIG'A4--M6DZ7"I A0LI&$ZEH*C<!).HR+00(
M?H^UK-XOX6Q'T\D SHQPPI3BZP9U1QS7V12[@S'A!?1(I8.&#FLN!)N+P]N@
MH>=&6Y3:H\9-ZC9D0_]%""H\<RR#N7-;RS>AYIKEF<(9SL?8?QGJX#IB%C0\
M##4JEDZ+HU8:,S2/BV%,L[JR56([E8I(XV)4AY\$_]D77!@LOQ]7/^%MEPE*
M$$:4W7N\]SE2M$S!3!&M#VW@MJ9^^QP1;"#BR@;CV"_N@]W_GVB4''%FZ+ND
MQL0>.:==MDL&^F"/E _E7VX3J>+M9>V?U.&70J$"/Q ]$HT^MG<Z?8NDWDZ2
M>!N0^ 0XF>U1K^=TS^9N&6@7X __E4S@X+ (K'&H439U-CAAP]L$>*!<(IW)
M9IX"=V<";J'+3!W^%T<&;=TVJ>&R)X#*'0"?#V^3M[YC4##AT5-@I&YK;>HP
M]S9U*_V@ N+*9T^!<XBX5'Q8Z1F4%@)O6/J0N&)HL,^1)JC?+DDF;$'JO M-
MSEF?5*TN-3?5@TU P.%-J>@Z[P7]=.[:!AWN$M,RF7S)![NHL<Q!4Y"_<5UG
MIC0,_!4:GGM=@*4IG1^(*GJ.@GO11%U!9P7V1$R@%, SOCM7 R+YL0KLQT-@
MGS]22"<B>:D4<X''0V3A6.#?F -3+G-5"W2CNZZ<'V%0(B>]W;;TD6A=T< L
M8@-7C_BO!3B"SQ&7=VV#*>/WAPH#5\.YEN<$HT$S*>-=GTS"]1DR \<4-&62
MJZ.GH^=<QS=-SAPBT6=S)YQB^20L@>G.X^'B<\?S1[.!IY8^BP7,^HXXI(+E
MQR0$D,;O9KJ!^!9T"MY,HQ5"('CHLS',6\_DBK%@4C/<[#+J>@[+^[:W"VT"
M8,&K\! (;0%\9<@+A_"9(!L]>XRQPY@9!XP;Q#C+6^PKC8 *RYEX_70>3.,X
M#^K$H(?,M+K<_-6PO^;+]+CS  ?O0UR88:AOE1,VJ%Q"X/?VX] ??N*_^_93
M?>P>Z5*GQ<VHL.Q= LU'#QJ6$%8W_,Q@38":V".HLE%J\):Y2S0P-^9$\ONN
M3<W)\:--VN4&^.M?8"#;NOPG4P@#I$;^/_\+YKZW'V] 6(-PX8>=7R42IZB:
MF'RKGL&B%=J2,<+D_/<H,OI<%VT<)?%/)-2[83F@,*KW@4&U#LD YUS+X/H>
M\5\&D-3[9"P[;C%) 1(0" B5S_]S@H9XB(A5DMM*J^:V3^+E>;E>.EQ?J]4+
M]5)MI4FME8J7U7*]7*JMKQ7.#TGINOBU</ZE1(H79V?E6JU\<;Z2]*=\^J^H
MV^9F2UCFYOK:8:P8(ZE$-K.SDC0G)AW7BM$6Z//11?4,Z)$@,?K"9=M.(BE7
MH]'HH:5YN.C /,"M-EHXCY?0/W/ZUL&I:5S2K@'PGK.RF1PCDM^.GDPO:T:\
M7U456^U)(B 1_&:U=%Y?7ZN6*A?5^DK3^@'$6?$<UZ.F6%\3%K33,*5+DFEB
M.229W= _$:M)1)NM- ^ ;,_A@C-W?:TTT-K4A "VH FD/;F3SJPT\1] QS$M
ML[X&PJPRVW($V< '*%Q&8<W-7$%8#\8ECGS-]$^[9'HFW9J:22LRJ5-2*9_Y
M4VK-YNZ/K7J[,6@]:4I5.RN?(WP@=G6 WH6V;9T.AX M,^=-N2%D(OF"U_*
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M0G,,GRP(ATR(>#0,I2BL; 6$4S:$-BZ^XR9$4QB=45)I8_MD(YXBFL%Q.]&
M> M")HSA_&I9QQ7K:_>>O*P*(R) ([.)<!AF Q&.36&I"II(9"2&'Z+!4V*X
MJ* 8Y\F "A#D&'L)C+OD(3)X"P@Z9*-;K%:*GV*D#L/)P7$EKO!5Q;S!0+ R
M8CH5>&2.-Q0G_) S.+T J)C12CE]$N_6+ZI 0YLWN+#D&09LV\#K^!$=B2G$
M@9;A"9".SC9Q[0^AH6.U&&*K,1OZ34$("/5C3HDXZ;<MX*$.(2?R$JAKH3
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M+U[\K-YT[LM'V;L?Z8I[E\YM_5LX_%*RCVN%SY\52_X?4$L! A0#%     @
MY8D65U<W&<(H P  XPL  !$              ( !     &-E;&,M,C R,S X
M,C(N>'-D4$L! A0#%     @ Y8D65QG2%A?]"@  @(8  !4
M ( !5P,  &-E;&,M,C R,S X,C)?;&%B+GAM;%!+ 0(4 Q0    ( .6)%E?X
M*@,+5 <  -57   5              "  8<.  !C96QC+3(P,C,P.#(R7W!R
M92YX;6Q02P$"% ,4    " #EB197OZL:EG40  "T6   "@
M@ $.%@  97@Y.2TQ+FAT;5!+ 0(4 Q0    ( .6)%E>V-E41X L  "T[   *
M              "  :LF  !E>#DY+3(N:'1M4$L! A0#%     @ Y8D65Z1A
M^$=E%@  #)T   L              ( !LS(  &9O<FTX+6LN:'1M4$L%!@
0   &  8 ;@$  $%)      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
